) --




) hit a new 52-week high Thursday as it traded at $34.90 compared with its previous 52-Week high of $34.54. Crucell is changing hands at $34.52 with 17,935 shares traded as of 1:31 p.m. ET. Average volume has been 69,500 shares over the past 30 days.

Crucell has a market cap of $2.8 billion and is part of the

health care

sector and


industry. Shares are up 9.5% year to date as of the close of trading on Wednesday.

Crucell N.V., a biopharmaceutical company, engages in developing, producing and marketing products to combat infectious diseases with a focus on paediatric, travel and endemic, and respiratory markets.

TheStreet Ratings rates Crucell as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. You can view the full

Crucell Ratings Report


See all

52-week high stocks

or get investment ideas from our

investment research center